GlassScriptPhysician profile
Ana M Aparicio
NPI 1720033657
$88,606.79
in general payments reported to CMS, 2019-2025
26 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $3,566 · 2021: $2,164 · 2022: $9,121 · 2023: $14K · 2024: $25K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,650 · Food and Beverage: $4,238 · Travel and Lodging: $3,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,250.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,650.00 |
| Food and Beverage | $4,238.29 |
| Travel and Lodging | $3,793.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $14,036.86 | 2019-2025 | |
| Genzyme Corporation | $9,774.06 | 2019-2023 | |
| Astellas Pharma US INC | $7,975.61 | 2020-2025 | Xtandi |
| Pfizer INC. | $7,796.32 | 2020-2025 | |
| Boehringer Ingelheim Rcv Gmbh & Co Kg | $7,248.21 | 2025 | |
| Abbvie INC. | $7,104.03 | 2025 | |
| Daiichi Sankyo INC. | $6,313.58 | 2021-2025 | |
| Glaxosmithkline, LLC. | $5,540.83 | 2024-2025 | |
| Astellas Pharma Global Development | $4,360.00 | 2022-2024 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $4,128.68 | 2023-2024 | Opdivo |
| Novartis Pharmaceuticals Corporation | $2,519.30 | 2025 | |
| Janssen Biotech, INC. | $2,514.25 | 2019-2025 | Erleada, Balversa |
| Astrazeneca Pharmaceuticals LP | $2,450.43 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,163.00 | 2024 | |
| Janssen Scientific Affairs, LLC | $1,870.37 | 2022-2025 | Erleada, Akeega |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $915.31 | 2025 | Lynparza |
| Amgen INC. | $875.87 | 2020-2022 | |
| Exelixis INC. | $347.48 | 2023-2025 | Cabometyx |
| Dendreon Pharmaceuticals LLC | $225.34 | 2020-2024 | Provenge |
| Macrogenics, INC. | $155.65 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $133.09 | 2024 | Libtayo |
| Astellas Pharma Europe Bv | $71.55 | 2024 | Xtandi |
| Sanofi-Aventis U.S. LLC | $67.71 | 2021 | |
| Aveo Pharmaceuticals, INC. | $19.26 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Aparicio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.